Research Director Oncology
Centre for Human Drug Research
Leiden University, The Netherlands
1995 – 2004 Study of Medicine, Leiden University, Leiden, The Netherlands.
1996 Propaedeutic exam Medicine, Leiden University, Leiden, The Netherlands.
1999 – 2000 Chairperson of the Board of the Medical Interfacultary Congress Foundation (M.I.C.), Utrecht, The Netherlands.
2000 Doctoral exam Medicine, Leiden University, Leiden, The Netherlands.
2000 – 2002 Pre-Doctoral Research Fellowship in Ocular-Immunology, The Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts, USA.
2004 Doctor of Medicine (M.D.), Leiden University, Leiden, The Netherlands.
2005 – 2008 Post-Doctoral Research Fellowship in Tumor-Immunology, University of Maryland, Baltimore, Maryland, USA
2007 – 2010 Member of the Associate Member Council, American Association for Cancer Research, Philadelphia, PA, USA.
2009 – Present Member of the Medical Advisory Board of the Ocular Melanoma Foundation, Richmond, VA, USA
2009 – 2022 Present Resident and Research Group Leader in Hematology and Medical Oncology, University Hospital Erlangen, Erlangen, Germany
2012 Doctor of Philosophy (Ph.D). in Medicine, specifically Tumor-Immunology, Leiden University, Leiden, The Netherlands.
B.I.G. registration number: 19062838701 (NL Medical Doctor database)
2015- Principal Investigator of Project 4 “Tumor-associated lymphangiogenesis and its inhibition as a novel therapeutic strategy in conjunctival melanomas” in the DFG Research Unit FOR 2240 “Angiogenesis, Lymphangiogenesis and Cellular Immunity in Inflammatory Diseases of the Eye” at the Department of Medicine 5 Hematology and Medical Oncology at the University Hospital Erlangen
2018- Principal Investigator of Project P4 “The role of midkine in tumor-associated lymphangiogenesis and metastasis of ocular malignant melanoma” in the DFG Research Unit FOR 2240 “Angiogenesis, Lymphangiogenesis and Cellular Immunity in Inflammatory Diseases of the Eye” at the Department of Medicine 5 Hematology and Medical Oncology at the University Hospital Erlangen
2022 – Research Director Oncology, Centra for Human Drug Research, Leiden University, The Netherlands
2002 ARVO Research Travel Award: Association of Research in Vision and Ophthalmology, annual meeting; Joseph M. and Eula G. Lawrence Retina Research Foundation, Houston, TX, USA
2007 AACR – Aflac Inc. Scholar-in-Training Award, American Association for Cancer Research, annual meeting, Los Angeles, CA, USA
2010 OMF Junior Investigator Award, Ocular Melanoma Foundation, annual meeting, Boston, MA, USA
2000 – 2002 Research Scholarships of several scientific Foundations in the Netherlands
2006 – 2007 Post-Doctoral Research Stipend, Fight for Sight Inc., New York, NY, USA
Cursiefen C, Bock F, Clahsen T, Regenfuss B, Reis A, Steven P, Heindl LM, Bosch JJ, Hos D, Eming S, Grajewski R, Heiligenhaus A, Fauser S, Austin J, Langmann T. [New Therapeutic Approaches in Inflammatory Diseases of the Eye – Targeting Lymphangiogenesis and Cellular Immunity: Research Unit FOR 2240 Presents Itself]. Klin Monbl Augenheilkd. 2017 May;234(5):679-685.
Refaian N, Schlereth SL, Koch KR, Notara M, Hos D, Mescher M, Iden S, Bosch JJ, Jager MJ, Cursiefen C, Heindl LM. Comparing the Hem- and Lymphangiogenic Profile of Conjunctival and Uveal Melanoma Cell Lines. Invest Ophthalmol Vis Sci. 2015;56(9):5691-7
Gary R, Voelkl S, Palmisano R, Ullrich E, Bosch JJ, Mackensen A (2012) Antigen-specific transfer of functional programmed death ligand 1 from human APCs onto CD8+ T cells via trogocytosis. J Immunol. 188(2):744-52.
Bosch JJ (2012) Immunotherapy of uveal melanoma. Dev Ophthalmol. 49:137-49.
Haile ST*, Bosch JJ*, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, Britting S, Wolf JB, Ksander BR, Ostrand-Rosenberg S (2011) Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. J Immunol. 186:6822-9. *these authors contributed equally
Bosch JJ, Iheagwara UK, Reid S, Srivastava MK, Wolf J, Lotem M, Ksander BR, Ostrand-Rosenberg S (2010) Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8(+) cytotoxic, tumor-specific T cells. Cancer Immunol Immunother. 59:103-12.
Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, Ksander BR, Ostrand-Rosenberg S (2007) MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res. 67:4499-506.